HTG Molecular Announces Third Statement of Work for New Clinical Assay Development Program

TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program